A strong proponent of the value of orphan drugs, Shire Greece’s Managing Director, Christos Dakas, shares his insights on the recent merger with Baxalta, the necessity of exempting orphan and haemophilia drugs from clawbacks to circumvent market challenges for critical treatments, as well as his vision for the bright future of the newly-redefined company.
Shire’s 32 billion merger with Baxalta in June 2016 marks the creation of Shire as the largest biotech company focused solely on rare diseases. How has this significant change manifested itself in Greece?
"It is important to distinguish the Greek market before and after the financial crisis when characterizing it, although it has remained a good market in both circumstances."
